RCKT241115P25000
- 0.00
- 0.000.00%
Rocket Pharmaceuticals Newsroom
Analysts' Opinions Are Mixed on These Healthcare Stocks: Sight Sciences (SGHT) and Rocket Pharmaceuticals (RCKT)
Rocket Pharmaceuticals Price Target Maintained With a $52.00/Share by Needham
Rocket Pharmaceuticals Analyst Ratings
TD Cowen Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating
William Blair Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating
LifeSci Capital Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Raises Target Price to $55
Rocket Pharmaceuticals Analyst Ratings
Scotiabank Initiates Rocket Pharmaceuticals at Sector Outperform With $50 Price Target
Rocket Pharmaceuticals Is Maintained at Buy by Canaccord Genuity
Rocket Pharmaceuticals Price Target Maintained With a $38.00/Share by Canaccord Genuity
CCORF Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $38
A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $38 to $53
Needham Reiterates Buy on Rocket Pharmaceuticals, Maintains $52 Price Target
Rocket Pharmaceuticals Analyst Ratings
Buy Rating for Rocket Pharmaceuticals Amid Positive Projections for RP-A501 Danon Disease Study
Rocket Pharmaceuticals (RCKT) Receives a Buy From Bank of America Securities
Analysts Conflicted on These Healthcare Names: Henry Schein (HSIC), Zymeworks (ZYME) and Rocket Pharmaceuticals (RCKT)
Solid Clinical Progress and Strong Financial Position Reinforce Buy Rating for Rocket Pharmaceuticals
LifeSci Capital Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $53
Buy Rating Affirmed on Rocket Pharmaceuticals Amid Promising Gene Therapy Advances and Solid Financials